Table 3.
Correlations between donor activating KIR and clinical outcome. Clinical endpoints examined included overall survival (OS), disease-free survival (DFS), non-relapse mortality (NRM), acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD). Hazard ratios were measured by univariate Cox proportional hazard modeling. 95% confidence intervals are shown in brackets. Ratios were considered significant then p ≤ 0.05 (bold italics, boxed).
| OS | DFS | NRM | aGVHD | cGVHD | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio |
p | Hazard ratio |
p | Hazard ratio |
p | Hazard ratio |
p | Hazard ratio |
p | |
| KIR2DS1 | 1.2 (0.8-2.0) |
0.35 | 1.0 (0.6-1.8) |
0.87 | 1.2 (0.6-2.1) |
0.63 | 0.9 (0.5-1.7) |
0.76 | 0.9 (0.5-1.4) |
0.57 |
| KIR2DS2 | 0.8 (0.5-1.3) |
0.44 | 0.9 (0.5-1.5) |
0.64 | 0.8 (0.5-1.5) |
0.55 | 1.0 (0.6-1.8) |
0.99 | 1.0 (0.3-3.2) |
0.98 |
| KIR2DS3 | 1.0 (0.6-1.7) |
0.91 | 0.7 (0.3-1.3) |
0.23 | 1.1 (0.6-2.1) |
0.79 | 0.9 (0.5-1.8) |
0.84 |
0.5 (0.3-0.9) |
0.03 |
| KIR2DS4 | 0.8 (0.5-1.3) |
0.31 | 1.2 (0.7-2.1) |
0.51 | 0.7 (0.4-1.4) |
0.34 | 0.7 (0.4-1.3) |
0.26 | 1.2 (0.8-1.9) |
0.43 |
| KIR2DS5 | 1.2 (0.7-1.9) |
0.5 | 1.2 (0.6-2.0) |
0.70 | 1.0 (0.5-1.9) |
0.97 | 0.9 (0.5-1.6) |
0.66 | 1.0 (0.6-1.5) |
0.84 |
| KIR3DS1 | 1.2 (0.7-1.9) |
0.46 | 0.9 (1.5-1.6) |
0.75 | 1.1 (0.6-2.0) |
0.74 | 1.1 (0.6-1.9) |
0.86 | 1.0 (0.6-1.6) |
0.97 |